Head & Neck Cancer | Topics

 
Pembrolizumab Plus Cetuximab Demonstrate Promising Clinical Activity for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
July 28, 2021

Data from a phase 2 clinical trial with pembrolizumab and cetuximab yielded promising clinical activity in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer
July 17, 2021

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
July 16, 2021

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.